Mereo BioPharma Group plc Notification of PDMR Dealing (9821V)

TIDMMPH

RNS Number : 9821V

Mereo BioPharma Group plc

13 August 2020

Mereo BioPharma Group plc

Notification of PDMR Dealing

London and Redwood City, Calif ., August 13, 2020 - Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), "Mereo" or "the Company", a clinical-stage biopharmaceutical company focused on oncology and rare diseases, received notification that on August 12, 2020 John Lewicki, Chief Scientific Officer of Mereo, was granted options over 100,000 American Depositary Shares (ADSs) under the Mereo BioPharma Group plc 2019 equity incentive plan for no consideration. The exercise price for these options is USD 2.77 per ADS.

Option grants were also made to other Company personnel over a further 100,000 ADSs at the same exercise price.

This announcement and the notification below is made in accordance with the EU Market Abuse Regulation. The PDMR disclosure form required under the EU Market Abuse Regulation follows.

 
 1    Details of the person discharging managerial responsibilities 
 a)   Name                      John Lewicki 
     ------------------------  -------------------------------------------------- 
 2    Reason for the notification 
     ---------------------------------------------------------------------------- 
 a)   Position/status           Chief Scientific Officer 
     ------------------------  -------------------------------------------------- 
 b)   Initial notification/     Initial notification 
       Amendment 
     ------------------------  -------------------------------------------------- 
 3    Details of the issuer, emission allowance market participant, 
       auction platform, auctioneer or auction monitor 
     ---------------------------------------------------------------------------- 
 a)   Name                      Mereo BioPharma Group plc 
     ------------------------  -------------------------------------------------- 
 b)   LEI                       213800U8JQHIJOS5AS09 
     ------------------------  -------------------------------------------------- 
 4    Details of the transaction(s): section to be repeated for 
       (i) each type of instrument; (ii) each type of transaction; 
       (iii) each date; and (iv) each place where transactions have 
       been conducted 
     ---------------------------------------------------------------------------- 
 a)   Description of            AMERICAN DEPOSITARY SHARE (ADS) EACH REPRESENTING 
       the financial             5 MEREO BIOPHARMA GROUP PLC ORDINARY SHARES 
       instrument, type          OF GBP0.003 EACH 
       of instrument 
       and identification 
       code 
     ------------------------  -------------------------------------------------- 
 b)   Nature of the             GRANT OF AN OPTION (FOR NO CONSIDERATION) 
       transaction               UNDER THE MEREO BIOPHARMA GROUP PLC 2019 
                                 EQUITY INCENTIVE PLAN. THE EXERCISE PRICE 
                                 IS US$2.77 PER ADS (FAIR MARKET VALUE AT 
                                 GRANT) 
     ------------------------  -------------------------------------------------- 
 c)   Price(s) and                Price(s)            Volume(s) 
       volume(s)                   No consideration    100,000 
                                                      ---------- 
     ------------------------  -------------------------------------------------- 
 d)   Aggregated information: 
       volume, Price 
     ------------------------  -------------------------------------------------- 
 e)   Date of the transaction   12-08-2020 
     ------------------------  -------------------------------------------------- 
 f)   Place of the              OUTSIDE OF A TRADING VENUE 
       transaction 
     ------------------------  -------------------------------------------------- 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

DSHGZGMRGZDGGZZ

(END) Dow Jones Newswires

August 13, 2020 02:00 ET (06:00 GMT)